Posted by Diane Farsetta on May 05, 2009

The pharmaceutical company Merck "paid an undisclosed sum to Elsevier to produce several volumes of a publication that had the look of a peer-reviewed medical journal, but contained only reprinted or summarized articles -- most of which presented data favorable to Merck products." The Australasian Journal of Bone and Joint Medicine carried "ads for Fosamax, a Merck drug for osteoporosis, and Vioxx" and "appeared to act solely as marketin

Posted by Bob Burton on April 28, 2009

An internal document (pdf) of the Global Climate Coalition (GCC) -- an industry front group that disbanded in 2002 -- reveals that when the group chose to promote doubt about the reality of global warming it was ignoring the views of its own scientific a

Posted by Bob Burton on March 03, 2009

The core of the small global network of global warming skeptics are once more gathering at a conference organized by the Heartland Institute, a corporate and foundation funded think tank based in Chicago.

Posted by Sheldon Rampton on February 24, 2009

"Biotechnology companies are keeping university scientists from fully researching the effectiveness and environmental impact of the industry’s genetically modified crops, according to an unusual complaint issued by a group of those scientists," reports Andrew Pollack.

Posted by Judith Siers-Poisson on February 11, 2009

A new study found that there is a higher health cost associated with corn-based biofuels than with traditional energy forms.

Posted by Judith Siers-Poisson on February 02, 2009

The U.S. House of Representatives voted to strengthen protections for whistleblowers, especially those that work for the Transportation Security Administration (TSA) and in other areas of national security.

Posted by Diane Farsetta on January 30, 2009

In 2002, an independent study on hormone replacement therapy was halted, because the drugs were strongly linked to an "increased risk for breast cancer, heart disease, stroke and blood clots" in women. The same year, the University of Wisconsin-Madison began offering an online course, "funded entirely by a $12 million grant from Wyeth Pharmaceuticals," that "promoted hormone therapy, touted its benefits and downplayed its risks." Wyeth makes two hormone therapy drugs, Prempro and Premarin.

Posted by Diane Farsetta on December 23, 2008

According to internal documents, the pharmaceutical company Wyeth "paid ghostwriters to produce medical journal articles favorable to its female hormone replacement therapy Prempro." As early as 1997, Wyeth paid the "medical writing firm" DesignWrite to publish favorable journal articles about Prempro under academics' names.



Subscribe to Science